Jinan, China, 17 November 2021 — Shanghai MicroPort MedBot (Group) Co., Ltd. (MicroPort® MedBot) recently attended the 28th National Seminar for Laparoscopic Surgery Demonstration, to launch their DFVision® 3D Electronic Laparoscope (DFVision®). The event - a grand academic gathering in the field of laparoscopy in China – was attended by industry experts and live broadcasted online, garnering over 59,000 views.
MicroPort® MedBot is the first Chinese-developed 3D electronic laparoscope to be admitted to the Special Approval Procedure for Innovative Medical Devices (the ‘Green Path’) in China, and was launched during the opening ceremony of the Seminar. Having received a medical device registration certificate by the National Medical Products Administration (NMPA) in June 2021, the DFVision® is one of the first commercially available 3D electronic laparoscopic instruments in China to be developed by a Chinese-based company, thus accelerating the process of introducing domestic 3D electronic laparoscopes to replace overseas products.
DFVision® adopts high-resolution imaging objective lenses in the structure of an electron microscope, which not only provides dual full-HD images but also significantly reduces its weight, thus providing greater convenience for surgeons. The three-dimensional and longitudinal field-of-view provided by DFVision® is crucial for precise release, suturing and knotting during the procedure. It not only effectively reduces the operation time, improves the quality and efficiency of the procedure, but also overcomes the limitations of traditional two-dimensional laparoscopy. These features make it easy for surgeons in various departments, such as general surgery, gynecology, and urology.
Chair of the Seminar, Prof. Sanyuan Hu, an academic leader of the Health System of Shandong province and President of the First Affiliated Hospital of Shandong First Medical University, said, "The use of medical devices such as the DFVision® 3D Electronic Laparoscope will undoubtedly facilitate the development of the high-end medical device manufacturing industry in China. It will promote the development of the medical industry as a whole, not to mention the high-quality and high-standard treatment solutions for the benefit of more patients. We hope that MicroPort® MedBot will continue to develop more medical products – and especially surgical robots.”
Mr. Yu Liu, Chief Commercial Officer of MicroPort® MedBot, stated, "This year is the thirtieth year since laparoscopic technology became available in China. It is also the year in which a registration certificate was granted to DFVision®, the first commercialized product independently-developed and launched by MicroPort® MedBot. We hope that under the guidance and leadership of all experts, we will jointly promote product development and iterative enhancement.”
About Shanghai MicroPort MedBot (Group) Co., Ltd.
MicroPort® MedBot is a subsidiary of Shanghai MicroPort Medical (Group) Co., Ltd. (MicroPort®). MicroPort® started its strategic development of medical robots in 2014 and has since been engaged in independent research and development of endoscopic surgical robots. Over the years, MicroPort® MedBot has focused on the development and commercialization of minimally invasive and noninvasive surgical robots, with integrated solutions gradually created for multiple clinical applications on five “golden paths”, namely laparoscopy, orthopedics, vascular intervention, natural orifice surgery, and percutaneous puncture.